TAGS: A Phase 3, Randomised, Double-blind Study of Trifluridine/Tipiracil ( TAS-102) Versus Placebo in Patients With Refractory Metastatic Gastric Cancer. - ppt download
TAGS: A Phase 3, Randomised, Double-blind Study of Trifluridine/Tipiracil ( TAS-102) Versus Placebo in Patients With Refractory Metastatic Gastric Cancer. - ppt download
Ramucirumab beyond progression plus TAS‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy - Goetze - 2023 - International Journal of Cancer - Wiley Online Library
Scenario 1. FLOT, TAS-102, IOs Do They Improve the Lives of Patients With Gastric Cancer? - ppt download
Cancers | Free Full-Text | Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer
Targeted and novel therapy in advanced gastric cancer | Experimental Hematology & Oncology | Full Text
Relative tumor volume (RTV) (a) and body weight change (BWC) (b) in... | Download Scientific Diagram
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
OncLive - The Japanese Ministry of Health, Labour and Welfare has approved TAS-102 (trifluridine/tipiracil; Lonsurf) for the treatment of patients with unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy.
Cancers | Free Full-Text | Recent Developments of Systemic Chemotherapy for Gastric Cancer
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
Gastric cancer: Translating novels concepts into clinical practice - ScienceDirect
Late-line treatment in metastatic gastric cancer: today and tomorrow | Semantic Scholar
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Result of the PII trial of TAS-102 in third/fourth line colorectal... | Download Scientific Diagram
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
Evolving Immuno-Chemotherapeutic Paradigms in Esophageal and Gastric Cancers | Published in healthbook TIMES Oncology Hematology
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase
Late-line treatment in metastatic gastric cancer: today and tomorrow | Semantic Scholar
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
Dihydroartemisinin suppresses proliferation, migration, the Wnt/β‑catenin pathway and EMT via TNKS in gastric cancer Corrigendum in /10.3892/ol.2021.13152
Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer - YouTube
Gastric Cancer Foundation FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer | Gastric Cancer Foundation
Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience | Gastric Cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma | Journal of Hematology & Oncology | Full Text
